The treatment of macular edema associated with various retinal diseases, including DME (Figure 1), is currently dependent on the repeated intravitreal injection of different anti-vascular endothelial growth factor (anti-VEGF) agents [2–6]. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.